The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer.

Klintman, Marie; Forsare, Carina; Ahlin, Cecilia; Beglerbegovic, Sanda; Fjällskog, Marie-Louise; Grabau, Dorthe; Gudlaugsson, Einar; Janssen, Emiel A M; Lövgren, Kristina; Skaland, Ivar; Bendahl, Pär-Ola; Malmström, Per; Baak, Jan P A; Fernö, Mårten

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0081902

2013

Link to publication

Citation for published version (APA):
Klintman, M., Forsare, C., Ahlin, C., Beglerbegovic, S., Fjällskog, M-L., Grabau, D., Gudlaugsson, E., Janssen, E. A. M., Lövgren, K., Skaland, I., Bendahl, P-O., Malmström, P., Baak, J. P. A., & Fernö, M. (2013). The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer. PLoS ONE, 8(12), [e81902]. https://doi.org/10.1371/journal.pone.0081902

Total number of authors:
14

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer

Marie Klintman1,2*, Carina Strand1, Cecilia Ahlin3, Sanda Beglerbegovic4, Marie-Louise Fjällskog5, Dorthe Grabau6, Einar Gudlaugsson7, Emiel A. M. Janssen7, Kristina Lövgren1, Ivar Skaland7, Pär-Ola Bendahl1, Per Malmström1,2, Jan P. A. Baak7, Mårten Fernö1

1 Department of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden, 2 Skåne Department of Oncology, Skåne University Hospital, Lund, Sweden, 3 Department of Oncology, Örebro University Hospital, Örebro, Sweden, 4 Division of Pathology, Växjö Central Hospital, Växjö, Sweden, 5 Department of Clinical Sciences, Division of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden, 6 Department of Clinical Sciences, Division of Pathology, Lund University and Skåne University Hospital, Lund, Sweden, 7 Department of Pathology, Stavanger University Hospital, Stavanger, Norway

Abstract

Proliferation, either as the main common denominator in genetic profiles, or in the form of single factors such as Ki67, is recommended for clinical use especially in estrogen receptor-positive (ER) patients. However, due to high costs of genetic profiles and lack of reproducibility for Ki67, studies on other proliferation factors are warranted. The aim of the present study was to evaluate the prognostic value of the proliferation factors mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A and Ki67, alone and in combinations. In 222 consecutive premenopausal node-negative breast cancer patients (87% without adjuvant medical treatment), MAI was assessed on whole tissue sections (predefined cut-off ≥10 mitoses), and PPH3, cyclin B1, cyclin A, and Ki67 on tissue microarray (predefined cut-offs 7th decile). In univariable analysis (high versus low) the strongest prognostic proliferation factor for 10-year distant disease-free survival was MAI (Hazard Ratio (HR)=3.3, 95% Confidence Interval (CI): 1.8-6.1), followed by PPH3, cyclin A, Ki67, and cyclin B1. A combination variable, with patients with MAI and/or cyclin A high defined as high-risk, had even stronger prognostic value (HR=4.2, 95%CI: 2.2-7). When stratifying for ER-status, MAI was a significant prognostic factor in ER-positive patients only (HR=7.0, 95%CI: 3.1-16). Stratified for histological grade, MAI added prognostic value in grade 2 (HR=7.2, 95%CI: 3.1-38) and grade 1 patients. In multivariable analysis including HER2, age, adjuvant medical treatment, ER, and one proliferation factor at a time, only MAI (HR=2.7, 95%CI: 1.1-6.7), and cyclin A (HR=2.7, 95%CI: 1.2-6.0) remained independently prognostic. In conclusion this study confirms the strong prognostic value of all proliferation factors, especially MAI and cyclin A, in all patients, and more specifically in ER-positive patients, and patients with histological grade 2 and 1. Additionally, by combining two proliferation factors, an even stronger prognostic value may be found.

Introduction

To avoid overtreatment of low-risk early breast cancer patients, and at the same time justify dose-intensive treatments for high-risk patients, better tools are needed when estimating risk and deciding on adjuvant medical treatment. Studies on genetic profiles, where the main common denominator is proliferation genes [1], have identified groups with prognostic
There have been questions as to the reproducibility of the clear and contrast-rich PPH3 staining has an advantage of factor Ki67 is now instead recommended for use for guidelines, MAI is highly reproducible [14,20,24].

There is however still no consensus on how to approximate of the biological intrinsic subtypes identified by genetic arrays [10]. More specifically, proliferation is used to distinguish between the “luminal A”- and “luminal B”-like subtypes. There is however still no consensus on how to assess Ki67, or which cut-off to choose, and international multicenter reproducibility studies are lacking, which limits the clinical value of Ki67 [11]. A recent study showed that subjective counts of Ki67 is poorly reproducible even when assessed by experienced pathologists, and inferior to digital image analysis (DIA) [12]. However subjective counts are still most commonly used. The strong prognostic value of the proliferation factor mitotic activity index (MAI) has been shown in a number of publications [13–19], even prospective studies [20,21]. There have been questions as to the reproducibility of MAI [22,23], but, when adhering to the recommended guidelines, MAI is highly reproducible [14,20,24]. Phosphohistone H3 (PPH3) is a protein involved in chromatin condensation and decondensation and is present in the G2 to M transition [25,26]. PPH3 has been shown to have a strong prognostic value in lymph-node negative breast cancer, and the clear and contrast-rich PPH3 staining has an advantage of being easily assessed with high inter-observer reproducibility [27–29]. Cyclin B1 regulates onset of mitosis, and high levels of cyclin B1 in breast cancers has in several studies been shown to be a negative prognostic marker [30–33]. High levels of the S-phase specific cyclin A, is also associated with a worse outcome in breast cancer [34–36].

The aim of the present study on premenopausal node-negative breast cancer patients was to investigate the prognostic value of the proliferation factors MAI, PPH3, cyclin B1, cyclin A, and Ki67. Secondly, this study aimed at investigating whether the prognostic value was dependent on ER-status and histological grade, and if the prognostic value of proliferation is strengthened when two proliferation factors are combined.

Material and Methods

Ethics Statement

The study was approved by the ethics committee of Lund University Hospital (LU 240-01). The study protocol contained a written patient information sheet which was given to all patients and a written instruction for the doctor on how the information should be given to the patients. This was followed by verbal informed consent which was documented in the patients’ records. Written informed consent was not required by the Ethics Committee of Lund when this study was conducted, and the above mentioned procedure was preferred in national trials and approved by the ethics committee of Lund University Hospital prior to the initiation of the study.

Patients

The initial patient population consists of 237 node-negative premenopausal patients who from 1991-1995 had been included in a prospective study on the prognostic value of S-phase fraction [37]. In total 222 patients were included in this study. In 14 cases no paraffin blocks were available at the pathology departments, and the remaining loss is specified separately for each proliferation factor. Detailed information on primary surgery, adjuvant radiotherapy and adjuvant medical treatment have been described earlier [37], and patient and tumour characteristics can be found in Table 1.

The median follow-up was 10.8 years for the end-point distant disease-free survival (DDFS) for patients alive and free from distant metastases at the last review of the patients’ records. Data from the first 10 years after diagnosis are presented. Whenever applicable, the REMARK recommendations for reporting of tumour marker studies were followed [38].

| Table 1. Characteristics of 222 premenopausal patients with node-negative breast cancer. |
|---------------------------------|-----------------|---------------|
| Age, years | Median | 47 |
| Tumour size, mm | Median | 15 |
| Range | 5-45 |
| No. of lymph nodes removed | Median | 9 |
| Range | 0-42* |
| Primary treatment, n | Breast conserving surgery without radiotherapy | 57 |
| Breast conserving surgery + postoperative radiotherapy | 106 |
| Modified radical mastectomy without radiotherapy | 52 |
| Modified radical mastectomy + postoperative radiotherapy | 7 |
| Adjuvant medical treatment, n | All | 29 |
| Adjuvant endocrine treatment | 8 |
| Tamoxifen 20 mg daily for 5 years | 7 |
| Oophorectomy | 1 |
| Adjuvant chemotherapy (CMF i.v.), nine cycles** | 21 |
| Local/locoregional recurrence***, No. of patients | ≤ 10 years | 32 |
| Distant metastases, No. of patients | ≤ 10 years | 48 |
| DDFS, % (95% CI) | 10 years | 78 (72-83) |
| Overall survival, % (95% CI) | 10 years | 80 (74-84) |

* One patient with axillary exeresis and no identified lymph nodes.

** CMF, cyclophosphamide, methotrexate, and 5-fluorouracil.

*** diagnosed as only events, or before distant recurrences.

doi: 10.1371/journal.pone.0081902.t001
Histological grading, ER and progesterone receptor (PR) analyses

Tumour grading was performed according to Elston and Ellis and as previously described [37,39]. ER and PR status were analyzed by enzyme immunoassay (EIA) on cytosol samples as previously described [37].

Human epidermal growth factor receptor 2 (HER2) status

HER2 protein was analyzed as previously described [40]. Amplified tumours and tumours with Herceptest 3+ in which fluorescent in situ hybridization analysis was non-evaluable were considered HER2-positive.

MAI

MAI was assessed by one experienced pathologist (JB) on lightly stained haematoxylin-eosin whole sections according to the MMMCP 1987 protocol [41]. The mitotic figures were carefully defined to avoid inclusion of apoptotic and necrotic cells. At low magnification, the area with subjectively the highest proliferation in the periphery of the tumour with invasive cancer, no necrosis or extensive inflammation, with an invasive component of at least 3 mm diameter was identified. Starting from this area, structures that were undeniable mitotic figures were identified (if necessary after focusing up and down) and counted at 400x magnification (objective 40x, field diameter 450 µm at specimen level) in 10 consecutive fields of view (FOV). Cases with thick or poorly fixed/stained sections (n=1), with extensive cancer in situ (CIS) or inflammation (n=8), or with an invasive area of <3 mm diameter (n=5) were excluded. In 14 cases, there were no available H&E sections left for evaluation. The MAI is defined as the total number of mitoses in an area in the section of 1.59 mm². The same cut-off as in previous publications was chosen, with ≥10 mitoses defined as high risk [20,24]. In all cases with MAI values between 5 and 15, a second assessment was later performed without knowledge of the results of the first assessment, and the highest value was chosen. In case of discrepancies of >3 mitoses, a third measurement was performed, and the highest value of the two assessments closest to each other was chosen for further analysis. Data on MAI was available for 195 patients.

Tumour Tissue Microarray (TMA) for assessment of cyclin B1, Ki67, cyclin A, and PPH3

The TMA was constructed as previously described with two 0.6 mm cores available for stainings for Ki67, cyclin B1, cyclin A, and two 1 mm cores for PPH3 [40]. Cores were taken from representative areas of the tumour, mainly from the periphery, but also from more central parts of the tumour.

Cyclin B1, Ki67 and cyclin A

Assessment of cyclin B1, Ki67, and cyclin A were all done in high-power fields (40X objective) using a light microscope. Cyclin B1 was assessed as previously described [30]. Antigen retrieval was performed in Tris-EDTA pH 9 buffer in a pressure cooker for 4 minutes at 121°C. Slides were stained with a cyclin B1 antibody diluted 1:200 (rabbit monoclonal cyclin B1 1495-1, Epitomics Inc Burlingame, CA, USA) in an Autostainer (DakoCytomation) for 30 minutes at room temperature. Diaminobenzidene (DAB) was used as chromogen, and 200 tumour cells were manually counted by two investigators. 5 cases were excluded, as there were fewer than 200 tumour cells in the TMAs. The level of agreement between the two readers was good (correlation coefficient 0.91 between estimated proportions and kappa value 0.77 when applying the cut-off defined below to both series), and results from only one of the readers was chosen for further analysis. Data on cyclin A and Ki67 was already available and assessments and reasons for exclusion have been described previously [34,40]. For cyclin A 200 cells were counted manually by two investigators. The level of agreement between the two readers was good (kappa value 0.71), and the results from the more experienced of the two investigators was chosen for further analyses. Four cases were excluded as there were no or less than 200 cancer cells in the TMA. Ki67 had also been assessed previously by three independent readers. A senior pathologist used a semiquantitative approach, the other two readers manual counting of all tumour cells in a TMA core. The level of agreement between readers was found to be good (kappa values of 0.83-0.88), and the semiquantitative assessments were chosen for further analyses. 23 cases were excluded due to staining difficulties (n=16) or loss of individual tumour sections in the TMA (n=7). The 7th decile was pre-defined as cut-off, as in previous publications, which for cyclin B1 corresponded to >12.5% positively stained cells [30], cyclin A >15% [36], and Ki67 >20% positively stained cells [40]. Data was available for 217, 218, and 199 patients for cyclin B1, cyclin A, and Ki67, respectively.

PPH3

Antigen retrieval was performed in Tris-EDTA buffer (pH 9.0) and heated for 3 minutes at 110°C, followed by 10 minutes at 95°C and then cooled to 20°C. Slides were stained in a Dako Autostainer. The rabbit polyclonal anti-phosphohistone H3 (ser 10 Upstate #06-570, Lake Placid, NY, USA) at 1:1500 dilution was used and incubated for 60 minutes at 22°C. DAB was used as chromogen. Assessment of PPH3 was done under a light microscope in high power fields (40X objective). All positively stained nuclei in the invasive tumour in a TMA core were counted, disregarding nuclei with fine granular staining as they are not in the G2 phase. Similar to assessment of MAI, previous assessments of PPH3 have been performed on whole tissue sections, starting at the periphery of the tumour on 10 consecutive FOVs with a total area of 1.59 mm² [28]. Therefore in the present study the number of positively stained nuclei in one TMA core was multiplied with 1.59 and divided by the total area the TMA, 1.13mm². The 7th decile was chosen as pre-defined cut-off, the same distribution as for the other proliferation factors assessed on TMA, which corresponded to ≥7 positive cells. Two cases were excluded, as there were no positively stained cells in the TMA. Therefore data on PPH3 was available for 221 patients.
Statistics

The primary end-point was 10-year distant disease-free survival (DDFS). The Kaplan Meier method was used for estimation of DDFS, and the log-rank test for comparing survival in different strata. The Cox proportional hazards model was chosen for estimation of univariable- and multivariable hazard ratios (HR). Proportional hazards assumptions were checked graphically and by Schoenfeld’s test [42]. All factors were used as dichotomous covariates in the statistical analyses, with the exception of grade (three groups) and age, which was also analysed as a continuous variable. The null hypothesis of no prognostic effect by the different proliferation factors in ER-positive and ER-negative patients was evaluated using a Cox model with a term for the interaction between ER-status and the proliferation factor. Cut-off values were chosen before statistical analyses. Pearson's correlation coefficient (r), Pearson's χ² test, and for histological grade Pearson's χ² test for trend, were used for analyses of associations between factors. Kappa statistics were used to evaluate the agreement between readers regarding cyclin A, cyclin B1, and Ki67 status. All P-values corresponded to two-sided tests and p<0.05 was considered significant. The statistical calculations were performed using Stata version 12.1 (StataCorp 2012, College Station, TX, USA).

Results

Patient and tumour characteristics

During the first 10 years after diagnosis 32 patients had locoregional recurrences (as only events or diagnosed before distant metastases), 48 patients had distant recurrences, and 45 deaths were recorded (43 of breast cancer). The 10-year DDFS for all patients was 78% (95% confidence interval (CI): 72-83%), and 10-year overall survival (OS) was 80% (95%CI: 73-84%). Detailed patient characteristics can be found in Table 1. All proliferation factors were strongly correlated (r: 0.44-0.74), Table 2. High MAI, PPH3, cyclin B1, Ki67, and cyclin A were significantly associated with younger age, larger tumour size, ER-negativity, HER2-positivity, and high grade (data not shown).

Distant disease-free survival at 10 years

The analyses presented below are based on all the 222 patients in the study or on subsets based on ER-status or histological grade. Similar results, but generally stronger, were found when the 29 patients (13%) who had received any adjuvant medical treatment were excluded (data not shown).

Univariable analyses

In univariable analysis MAI (high: ≥10 versus low: <10) was the strongest proliferation factors for DDFS (HR=3.3, 95%CI 1.8-6.1, p<0.001), corresponding to a 10-year DDFS of 61% (95%CI: 48-73%) and 86% (95%CI: 78-90%) for high- and low-risk patients, respectively. This was followed by PPH3 (HR=2.4, 95%CI 1.4-4.3, p=0.002), cyclin A, Ki67, and cyclin B1, Table 3, Figure 1 a-e. HER2, PR, and age were also significant prognostic factors, but ER and tumour size were not, Table 3.

The prognostic value of proliferation stratified for ER-status and histological grade

When stratifying for ER-status, a very strong negative effect of high MAI was found in ER-positive patients (HR=7.0, 95%CI: 3.1-16, p<0.001) with a 10-year DDFS of 44% (95%CI: 22-65) and 87% (95%CI: 80-92%) for high- and low-risk patients, respectively. No prognostic effect was found in ER-negative patients (HR=1.3, 95%CI: 0.47-3.8, p=0.59), Figure 2a-b. The prognostic effect of MAI in ER-positive and ER-negative patients was further analyzed and found to differ corresponding to a significant interaction term (HR=5.0, 95%CI: 1.3-19, p=0.017). Similar effects were found for PPH3, cyclin B1, cyclin A, and Ki67, Table 3.

For histological grade, no added prognostic value for MAI was found in histological 3. However, a strong added prognostic effect was found in histological grade 2 (HR=7.2, 95%CI: 3.1-22, p=0.001) and in grade 1 (HR=11, 95%CI: 2.3-55, p=0.003), Figure 3a-c. Similar but weaker effects were found for PPH3, cyclin B1, cyclin A, and Ki67 (data not shown).

Combinations of proliferation factors

In a series of two-factor analyses one proliferation factor at a time was combined with MAI. Only patients who had data on both proliferation factors available for each two-factor analysis were included. Discordant cases for all combinations with MAI were found to have a significantly higher risk of recurrence than patients negative for both factors (p<0.001 for the combination MAI and cyclin A, log rank test), and no significant differences in distant recurrence rates compared to patients with both factors high, Figure 4a-d. Patients with at least one of the two proliferation factors positive were therefore defined as high-risk.

By combining MAI and cyclin A (N=193), the prognostic value was strengthened (HR=4.2 95%CI: 2.2-7.9, p<0.001), corresponding to a 10-year DDFS of 60% (95%CI: 48-71%) for the 35% high-risk patients (68/193), compared with 88%
Table 3. Univariable analysis of prognostic factors for 10-year distant disease-free survival for all 222 premenopausal patients with node-negative breast cancer (left), and for the ER-positive patients only (right).

| Factor          | All patients (n=222, 48 events) | ER-positive patients (n=148, 27 events) |
|-----------------|---------------------------------|----------------------------------------|
|                 | n  | Distant recurrence | Hazard Ratio | 95% Confidence Interval | p-value | n  | Distant recurrence | Hazard Ratio | 95% Confidence Interval | p-value |
| Age, years      | All | 222 | 48 | 22 | 0.91 | 0.87-0.95 | <0.001 | 148 | 27 | 18 | 0.89 | 0.84-0.95 | <0.001 |
|                 | >50 | 55  | 4  | 7  | 1.0  |           |        | 43  | 1  | 2  | 1.0  |           |        |
|                 | ≤50 | 167 | 44 | 26 | 4.1  | 1.5-11   | 0.007  | 105 | 26 | 25 | 12  | 1.7-90   | 0.014  |
| Tumour size, mm | All | 222 | 66 | 33 | 20  | 1.0      |        | 116 | 21 | 18 | 1.0  |           |        |
|                 | >20 | 156 | 15 | 27 | 1.5  | 0.80-2.7 | 0.21   | 32  | 6  | 19 | 1.0  | 0.42-2.6 | 0.92   |
| Histological grade | All | 217 | 1  | 69 | 14  | 0.37     | 0.18-0.78 | 0.09  | 77  | 7  | 12 | 0.25  | 0.09-0.65 | 0.005  |
|                 | 2   | 79  | 15 | 19 | 0.50 | 0.26-0.97 | 0.039  | 62  | 10 | 16 | 0.33 | 0.14-0.79 | 0.001  |
|                 | 3   | 69  | 23 | 33 | 1.0  |           |        | 25  | 10 | 40 | 1.0  |           |        |
| ER              | All | 222 | 148| 27 | 18  | 1.0      |        | 137 | 25 | 18 | 1.0  |           |        |
|                 | Pos | 2   | 18 | 1.0 |     |           |        | 11  | 2  | 2  | 1.0  |           |        |
|                 | Neg | 74  | 21 | 28 | 1.7  | 0.98-3.1 | 0.059  | 11  | 2  | 2  | 1.0  |           |        |
| PR              | All | 222 | 160| 28 | 18  | 1.0      |        | 137 | 25 | 18 | 1.0  |           |        |
|                 | Pos | 62  | 20 | 32 | 2.2  | 1.2-3.9  | 0.008  | 11  | 2  | 2  | 1.0  | 0.26-4.6 | 0.91   |
|                 | Neg | 56  | 14 | 42 | 2.2  | 1.0      |        | 11  | 4  | 36 | 2.7  | 0.92-7.7 | 0.070  |
| HER2            | All | 209 | 186| 32 | 17  | 1.0      |        | 131 | 23 | 18 | 1.0  |           |        |
|                 | Pos | 23  | 11 | 48 | 3.9  | 2.0-7.8  | <0.001 | 11  | 4  | 36 | 2.7  | 0.92-7.7 | 0.070  |
|                 | Neg | 183 | 145| 44 | 1.0  |           |        | 117 | 15 | 13 | 1.0  |           |        |
| MAI             | All | 195 | 138| 20 | 14  | 1.0      |        | 117 | 15 | 13 | 1.0  |           |        |
|                 | Low| 57  | 22 | 39 | 3.3  | 1.8-6.1  | <0.001 | 18  | 10 | 56 | 7.0  | 3.1-16   | <0.001 |
|                 | High| 63 | 23 | 42 | 2.2  | 1.4-4.3  | 0.002  | 41  | 12 | 29 | 2.4  | 1.1-5.2  | 0.029  |
| PPH3            | All | 221 | 153| 25 | 16  | 1.0      |        | 107 | 15 | 14 | 1.0  |           |        |
|                 | Low| 68  | 23 | 34 | 2.4  | 1.4-4.3  | 0.002  | 41  | 12 | 29 | 2.4  | 1.1-5.2  | 0.029  |
|                 | High| 154| 22 | 32 | 2.2  | 1.0      |        | 127 | 20 | 16 | 1.0  |           |        |
| Cyclin B1       | All | 217 | 162| 29 | 18  | 1.0      |        | 127 | 20 | 16 | 1.0  |           |        |
|                 | High| 55  | 18 | 33 | 2.2  | 1.2-3.9  | 0.010  | 16  | 6  | 38 | 2.9  | 1.2-7.2  | 0.023  |
| Cyclin A        | All | 218 | 150| 25 | 17  | 1.0      |        | 121 | 18 | 15 | 1.0  |           |        |
|                 | High| 68  | 23 | 34 | 2.4  | 1.3-4.2  | 0.003  | 24  | 9  | 38 | 3.1  | 1.4-7.0  | 0.001  |
| Ki67            | All | 199 | 136| 24 | 18  | 1.0      |        | 110 | 16 | 15 | 1.0  |           |        |
|                 | Low| 63  | 21 | 33 | 2.2  | 1.2-3.9  | 0.010  | 22  | 10 | 45 | 3.9  | 1.8-8.6  | 0.001  |
| MAI and/or PPH3 high | All | 194| 118| 16 | 14  | 1.0      |        | 101 | 12 | 12 | 1.0  |           |        |
| Factor | All patients (n=222, 48 events) | ER-positive patients (n=148, 27 events) |
|--------|--------------------------------|---------------------------------------|
|        | n | Distant recurrence | Hazard Ratio | 95% Confidence Interval | p-value | n | Distant recurrence | Hazard Ratio | 95% Confidence Interval | p-value |
|        | n | No | %  |  |  |  | No | %  |  |  |  |  |
| High  | 76 | 26 | 34 | 3.0 | 1.6-6.7 | <0.001 | 34 | 13 | 38 | 4.2 | 1.9-9.1 | <0.001 |
| Low   | 125 | 17 | 14 | 1.0 | 1.8-6.1 | <0.001 | 106 | 13 | 12 | 1.0 | 2.2-11 | <0.001 |
| High  | 66 | 24 | 36 | 3.3 | 2.2-7.9 | <0.001 | 25 | 11 | 44 | 4.8 | 2.9-14 | <0.001 |
| Low   | 108 | 15 | 14 | 1.0 | 1.8-6.5 | <0.001 | 95 | 12 | 13 | 1.0 | 2.5-12 | <0.001 |
| High  | 65 | 25 | 38 | 3.4 | 1.6-6.7 | <0.001 | 24 | 12 | 50 | 5.5 | 2.5-12 | <0.001 |
(95% CI: 81-93%) for the 65% low-risk patients (125/193). No such added prognostic value was found for combinations of MAI with PPH3, cyclin B1 or Ki67, Table 3.

Multivariable analyses
162 patients (35 events) had data available on all proliferation factors MAI, PPH3, cyclin B1, Ki67, and cyclin A. In multivariable analyses adjusted for age, ER-status, HER2-status, adjuvant medical treatment and one proliferation factor at a time, MAI (HR=2.7, 95% CI: 1.1-6.7, p=0.035), and cyclin A
Figure 2. 10-year distant disease-free survival of 195 premenopausal women with lymph-node negative breast cancer according to MAI-status in (a) ER-positive patients (b) ER-negative patients.
doi: 10.1371/journal.pone.0081902.g002

Figure 3. 10-year distant disease-free survival of 195 premenopausal women with lymph-node negative breast cancer according to MAI-status in (a) histological grade 1 (b) histological grade 2 (c) histological grade 3.
doi: 10.1371/journal.pone.0081902.g003
Figure 4. 10-year distant disease-free survival of 195 premenopausal women with lymph-node negative breast cancer with data available on MAI, with MAI combined with (a) PPH3 (b) cyclin B1 (c) cyclin A, and (d) Ki67 with patients stratified into four groups, with either 0, 1, or 2 factors positive. As can be seen in all figures, patients with at least one of the two proliferations factors positive have a significantly higher risk of recurrence than patients negative for both factors, and no significant differences in recurrence rates compared to patients with both factors positive.

doi: 10.1371/journal.pone.0081902.g004

Discussion

This study on premenopausal node-negative breast cancer patients with long-term follow up again proves the importance of proliferation, especially in ER-positive patients. As ER-negative patients have a worse prognosis, and in general a higher proliferation rate than the ER-positive patients [2,43], they would more often be offered chemotherapy as endocrine treatment is not an option. Studies have also shown that in ER-negative patients genes associated with immune response and the complement system are most important for prognosis, and that a good prognosis group could be found within this context for whom adjuvant chemotherapy may be avoided [44]. The majority of breast cancer patients are however ER-positive, and the main focus therefore lies in identifying ER-positive patients with a risk of recurrence sufficiently low to avoid extensive adjuvant treatment, and at the same time identify high-risk patients within a low-risk cohort. Studies on genetic
profiling have revealed that the main common denominator in genetic profiles is proliferation genes, and it is within these genes the prognostic information lies [1]. Results from the two prospective studies on genetic profiles, MINDACT and TailorX have not yet been published, and in the 2011 St Gallen guidelines Ki67 is recommended as the surrogate proliferation marker of choice to distinguish between the low- and high-proliferative ER-positive luminal subtypes. However, there is a lack of consensus on assessment of Ki67 and choice of cut-off, and the reproducibility has been questioned [11]. Therefore, studies assessing other proliferation markers are needed.

The present study proves all included proliferation factors to be of prognostic value in the whole patient cohort, but more specifically in ER-positive patients. All factors stratified ER-positive patients into a low- and a high-proliferating group, a “luminal A”- and a luminal B-like group, with significant differences in prognosis. No such effect was found in the ER-negative patients, which is probably due to the higher proliferation rates found in ER-negative patients [2,43].

MAI was the strongest prognostic proliferation factor, with as much as a three-fold hazard of distant recurrence at 10 years, both in univariable- and multivariable analysis, and a 7-fold hazard of distant recurrence in the ER-positive patients. MAI has the advantage, when it comes to clinical applicability, that evaluation of mitoses is already a part of routine histological grading. However, the protocol for assessment of MAI is more rigorous than mitosis assessment according to Elston and Ellis [39]. In the present study, when adhering to this stricter protocol of assessment of mitoses, the prognostic value of MAI surpasses histological grade and Ki67. This strong prognostic value of MAI confirms results from previous studies [13,15,18,20,41].

The other mitosis- and late G2-phase specific proliferation marker PPH3 also, as in previous studies [27–29], proved to be of strong prognostic value in all patients, and more specifically in ER-positive patients. PPH3 is a less extensively studied proliferation factor, and the staining is clear and contrast-rich, easily assessed, and with high inter-observer reproducibility [28]. Additionally, PPH3 does not stain apoptotic cells, which otherwise by routine assessment can be mistaken for mitotic cells. Lastly, PPH3 assessment only requires counting of positively stained cells, which is less time-consuming than assessment of Ki67. It could therefore be a support to MAI assessment. Similar to MAI, PPH3 and Ki67 values are higher in the periphery of the tumour, the growing zone, than in central less proliferative parts of the tumours. To facilitate comparisons between the different proliferation factors in the present study the predefined cut-offs chosen were the same for all factors assessed on TMA, the 7th decile, which for PPH3 corresponded to ≥7 positive cells in 10 consecutive FOVs. In previous publications on PPH3, the optimized cut-off of ≥13 positive cells was found when assessing PPH3 on whole sections, with assessments starting at the periphery. This cut-off corresponded to >35% PPH3 positive tumours, quite similar to the 7th decile chosen here [29]. In the present study, PPH3 was assessed on TMA cores which had been taken from both the periphery and the less proliferative centre of the tumour, which may explain why the same decile may correspond to different absolute cut-off values. Cyclin B1 also added prognostic value, although not as strong as MAI and PPH3.

Histological grade 2 patients constitute 30-60% of all patients, and they have a variable prognosis. We have previously shown that by stratifying grade 2 patients for another proliferation factor, Ki67, two groups with significant differences in prognosis were found, similar to grade 1 and grade 3 tumours, respectively [40]. These findings are in line with results for the genetic profile Genomic Grade Index, where one of the candidate genes is Ki67 [7]. Similar effects were found for grade 1 and 2 patients for all proliferation factors in the present study. However, as the numbers at risk with grades 1 and 2 and high MAI were few, the statistical power was low in these subgroup analyses, and results should be confirmed in larger patient series.

All single factors have their methodological advantages and disadvantages, and genetic profiles consist of multiple proliferation genes [1]. A recent study has also suggested that although all commercially available genetic profiles add independent prognostic value, the best prediction of recurrence

| Table 4. Multivariable analyses of 10-year distant disease-free survival in all premenopausal patients with node-negative breast cancer where complete data on all proliferation factors was available (n=162, left), and in the ER-positive patients only (n=114, right). |
|---|---|---|---|---|---|---|---|---|
| Factor | All patients (n=162, 35 events) | ER-positive patients (n=114, 23 events) | |
| | Hazard Ratio | 95% Confidence Interval | p-value | Hazard Ratio | 95% Confidence Interval | p-value |
| MAI high vs low | 2.7 | 1.1-6.7 | 0.035 | 5.9 | 2.4-15 | <0.001 |
| PPH3 high vs low | 1.4 | 0.66-3.1 | 0.37 | 1.8 | 0.70-4.8 | 0.22 |
| Cyclin B1 high vs low | 1.5 | 0.62-3.7 | 0.36 | 1.8 | 0.59-5.4 | 0.31 |
| Cyclin A high vs low | 2.7 | 1.2-6.0 | 0.019 | 3.1 | 1.2-8.0 | 0.016 |
| Ki67 high vs low | 1.8 | 0.81-4.1 | 0.15 | 3.6 | 1.4-8.9 | 0.007 |
| MAI and/or PPH3 high high vs low | 2.0 | 0.89-4.7 | 0.093 | 3.3 | 1.4-7.9 | 0.008 |
| MAI and/or cyclin B1 high high vs low | 2.6 | 1.1-6.2 | 0.027 | 4.0 | 1.6-10 | 0.003 |
| MAI and/or cyclin A high high vs low | 3.6 | 1.6-8.7 | 0.002 | 4.9 | 2.0-12 | <0.001 |
| MAI and/or Ki67 high high vs low | 2.9 | 1.3-6.8 | 0.013 | 4.7 | 1.9-11 | 0.001 |

All models are adjusted for age, ER-status (not in the ER-positive patients), HER2-status, and adjuvant medical treatment.

doi: 10.1371/journal.pone.0081902.t004

---

PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e81902
was found if profiles were combined [9]. We therefore hypothesised that by combining two factors, of which at least one was positive, the prognostic value could be strengthened. We could show that for the entire patient cohort, not only patients with both factors positive, but also those with at least one factor positive (11-20% of all patients), had a significantly worse prognosis than patients negative for both factors. The strongest combination in univariable analysis in the present study was MAI combined with cyclin A. As cyclin A is expressed in S-phase, and MAI in M-phase, they might complement each other as the combination covers a greater span of the cell cycle. This is in line with a recent study by Gudlaugsson et al in which Ki67 yielded additional prognostic information in low proliferative breast cancers, with either MAI or PPH3 [45]. In the present study other combinations with MAI did not strengthen the prognostic value of MAI, but this may have been due to the limited number of patients and events in the present study. As all factors add prognostic value in univariable analysis it is likely that more combinations could have added prognostic strength in a larger patient set.

Lastly, an important advantage of immunohistochemical (IHC) assessments compared to genetic profiling, is the possibility of selective analysis of the invasive tumour only, excluding normal cells, in situ components, and areas of inflammation and necrosis, which could contaminate samples sent for genetic profiling. Also, it allows for selective assessment of proliferation in the periphery of the tumour where the proliferation rates are the highest. With standardisation of IHC procedures and factors that influence reproducibility, such as choice of detection system and antibody, cut-offs, and tissue section thickness, the quality of the IHC stains and reproducibility can be significantly improved [12,46].

In conclusion, the proliferation factors MAI, PPH3, and cyclin A are all of strong prognostic value in node-negative breast cancer, specifically in ER-positive patients and patients with histological grade 2. MAI, followed by PPH3, and cyclin A, was the strongest prognostic proliferation factor in the present study. This study also suggests that the prognostic value of proliferation is improved when combining two proliferation factors, in the present study MAI with cyclin A, and this can be used when deciding on risk and choice of adjuvant medical treatment.

Ethical Standards

The study was approved by the ethics committee of Lund University Hospital (LU 240-01). The study protocol contained a written patient information sheet which was given to all patients and a written instruction for the doctor on how the information should be given to the patients. This was followed by verbal informed consent which was documented in the patients’ records. Written informed consent was not required by the Ethics Committee of Lund when this study was conducted, and the above mentioned procedure was preferred in national trials and approved by the ethics committee of Lund University Hospital prior to the initiation of the study.

Author Contributions

Conceived and designed the experiments: MK CS P-OB PM JB MF. Performed the experiments: MK CS CA SB DG KL P-OB PM JB MF. Analyzed the data: MK CS CA SB M-LF DG EG EJ KL IS P-OB PM JB MF. Contributed reagents/materials/analysis tools: MK CS CA SB M-LF DG EG EJ KL IS P-OB PM JB MF. Wrote the manuscript: MK CS CA SB M-LF DG EG EJ KL IS P-OB PM JB MF.

References

1. Wirapati P, Soriniou C, Kunkel S, Farmer P, Pradrervand S et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65. doi:10.1186/bcr1949. PubMed: 18662380.
2. Perou CM, Sartie T, Eibis MB, van de Rijn M, Jeffreys SS et al. (2000) Molecular portraits of human breast tumours. Nature 405: 747-752. doi:10.1038/35021093. PubMed: 10963602.
3. Paik S, Shak S, Tang G, Kim C, Baker J et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 350: 2817-2826. doi:10.1056/NEJMoa041588. PubMed: 15591335.
4. Sartie T, Perou CM, Tihsbirani R, Aas T, Geisler S et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. doi:10.1073/pnas.191367098. PubMed: 11553615.
5. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. doi:10.1038/415530a. PubMed: 11623860.
6. Ishiha AV, George J, Senko O, Mow B, Putti TC et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301. doi:10.1158/0008-5472.CAN-05-4414. PubMed: 17079448.
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272. doi:10.1093/jnci/djj052. PubMed: 16478745.
8. Harris L, Fritsche H, Menzel R, Norton L, Radvin P et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312. doi:10.1200/JCO.2007.14.2364. PubMed: 17954709.
9. Prat A, Parker JS, Fan C, Cheang MC, Miller LD et al. (2012) Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23: 2866-2873. doi:10.1093/annonc/mds080. PubMed: 22532584.
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747. doi:10.1093/annonc/mdr304. PubMed: 21709140.
11. Dowsett M, Nielsen TO, AHern R, Bartlett J, Coombes RC et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664. doi:10.1093/jnci/djr393. PubMed: 21960707.
12. Gudlaugsson E, Skandal I, Janssen EA, Smaland R, Shao Z et al. (2012) Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 61: 1134-1144. doi:10.1111/j.1365-2559.2012.04329.x. PubMed: 22963617.
13. Skandal I, van Diest PJ, Janssen EA, Gudlaugsson E, Baak JP (2008) Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum Pathol 39: 584-590. doi:10.1016/j.humpath.2007.08.016. PubMed: 18291440.
14. Baak JP, van Diest PJ, Janssen EA, Gudlaugsson E, Voorhorst FJ et al. (2008) Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 19: 649-654. PubMed: 18042836.
reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer 60: 55-61.

10. Baudin E, Bois RM, Gore E, Grimm B, Meunier B et al. (2008) Cyclin B1 and cyclin D1 in breast cancer. J Pathol 215: 264-274.

11. Rudolph P, Kühl M, Alm P, Fernö M, Kühling H et al. (2003) Differential prognostic impact of the cyclins E and B1 in premenopausal and postmenopausal women with lymph node negative breast cancer. Eur J Cancer 39: 2081-2087.

12. Suzuki T, Urano T, Miki Y, Moriya T, Akahira J et al. (2007) Nuclear cyclin B1 in human breast carcinomas as a potent prognostic factor. Cancer Sci 98: 644-651.

13. Boiesen P, Bendahl PO, Fjällskog ML, Hedenfalk I et al. (2012) Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat 131: 33-40.

14. Aaltonen L, Nilsson C, Holmquist M, Holmberg L, Linsson C et al. (2010) Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer. Acta Oncol 49: 816-20. PubMed: 20030724.

15. Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7: 1716-1723. PubMed: 11410511.

16. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV et al. (2000) Histologic grading in breast cancer--reproducibility between pathologists. Acta Oncol 39: 41-45. PubMed: 10409442.

17. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E et al. (2000) Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 39: 41-45. PubMed: 10409442.

18. Harvey JM, de Klerk NH, Sterrett GF (1992) Histological grading in breast cancer: interobserver agreement, and relation to other prognostic factors including ploidy. Pathology 24: 63-68. DOI: 10.3109/00313029209663625. PubMed: 1641262.

19. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM et al. (1992) Reproducibility of mitosis counting in 2,459 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23: 599-6001. DOI: 10.1012/0002-9351(1992)0505.511. PubMed: 16135467.

20. Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7: 1716-1723. PubMed: 11410511.

21. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV et al. (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients. J Clin Oncol 23: 5993-6001. DOI: 10.1200/JCO.2005.05.511. PubMed: 16135467.

22. Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ et al. (2010) Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer. Breast Cancer Res Treat 121: 35-40. DOI: 10.1007/s10549-009-9442-x. PubMed: 19588929.

23. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E et al. (2000) Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 39: 41-45. DOI: 10.1080/028418600430950. PubMed: 11410511.

24. Ahlin C, Zhou W, Holmquist M, Holmberg L, Nilsson C et al. (2009) Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Breast Cancer Res Treat 115: 2501-2506. DOI: 10.1007/1055-9656-EP-09-0169. PubMed: 19708846.

25. Malmström P, Bendahl PO, Boiesen P, Brünner N, Ildvall I et al. (2001) S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19: 2010-2019. PubMed: 11283134.

26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235. DOI: 10.1007/10549-006-9242-8. PubMed: 16932852.

27. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410. DOI: 10.1111/j.1365-2559.1991.tb01229.x. PubMed: 17570709.

28. Kimlmann T, Bendahl PO, Grabau D, Lövgren K, Malmström P et al. (2010) The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 23: 251-259. DOI: 10.1038/modpathol.2009.167. PubMed: 19935641.

29. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM et al. (1989) The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185: 664-670. DOI: 10.1016/S0344-0338(89)80213-4. PubMed: 2699694.

30. Schenklin B (1982) Partial residuals for the proportional hazards regression model. Biometrika 69: 239-241. DOI: 10.1093/biomet/69.1.239.

31. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398. DOI: 10.1073/pnas.1732912100. PubMed: 12917485.

32. Teschendorf AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157. DOI: 10.1186/gb-2007-8-8-r157. PubMed: 17683518.

33. Gudlaugsson E, Kjos J, Skalander I, Janssen EA, Smaaland R et al. (2013) Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T1(+) (2)(N0)(M0) breast cancer. PLoS Pathol 6: 1-8.

34. Skaland I, Nordhus M, Gudlaugsson E, Holmberg L, Kjellvekh HD et al. (2010) Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol 18: 90-96. DOI: 10.1097/PAI.0b013e3181b0e0ad. PubMed: 19961787.